31 results about "Hemopexin" patented technology

The present invention is directed to methods of producing recombinant functional heme-binding proteins with complete heme incorporation and purified preparations of the same. The present invention is further directed to methods of identifying agents that modulate the activity of heme-binding proteins.

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the secreted peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the secreted peptides, and methods of identifying modulators of the secreted peptides.

The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-microglobulin as markers for preeclampsia.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein.

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

The present invention aims at providing a method for determining at least one protein in the blood which is more precise while still being simple to implement. The inventors have exploited in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

Provided are in vitro serologic methods of assessing the presence of, and assessing the progression of, liver fibrosis in a subject. Also provided are methods of assessing efficacy of an agent for the treatment of liver fibrosis, and methods of treating liver fibrosis. The methods involve quantitatively measuring di-sialylated and mono-sialylated O-glycoforms of a peptide fragment of hemopexin (HPX) in a test serum sample obtained from a test subject, and comparing the measured amounts of di-sialylated and mono-sialylated O-glycoforms of the peptide fragment of hemopexin to a reference amount. In certain embodiments, the measuring is performed using LC-MS / MS-MRM (liquid chromatography / tandem mass spectrometry / multiple reaction monitoring). In certain embodiments, the measuring is performed using LC / MS3 (liquid chromatography with triple-stage mass spectrometric detection).

The invention belongs to the field of genetic engineering, and discloses a gene TaHBP1 with a heme-binding (Heme-binding) domain, its recombination interference carrier and its application. The cDNA sequence of the gene TaHBP1 with Heme-binding domain is SEQ ID NO.1 and the encoded amino acid sequence is SEQ ID NO.2. The gene is from common wheat (Triticum asetivum L.) Yangmai 158. The expression of TaHBP1 in powdery mildew-susceptible wheat variety Yangmai 158 was induced by powdery mildew, and the expression level was much higher than that in disease-resistant wheat variety Nannong 9918. The forward sequence of TaHBP1 was inserted between the BamHI and KpnI restriction sites of pWMB006, and the reverse sequence was inserted between SpeI and SacI of pWMB006 to obtain an interference expression vector, and the wheat variety Yangmai 158 susceptible to powdery mildew was transformed, and the positively transformed plants The powdery mildew resistance identification results showed that the reduced expression of TaHBP1 could improve the resistance of powdery mildew susceptible wheat cultivars to powdery mildew.

A compound of Formula I:wherein:Y is —C(O)NHR1 or —NHC(O)R1;R1 is aryl; is optionally substituted with one or more substituents selected from the group consisting of oxo, F, Cl, Br, I, alkyl, NH2, NHR4, NHC(O)R4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; or is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, NO2, alkyl, C(O)R4, C(O)NHR4, C(O)NR5R6, C(O)OH, C(O)OR4, NH2, NHR4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl;each R4 is independently alkyl, cycloalkyl, or aryl; each R5 is independently alkyl, cycloalkyl, or aryl; each R6 is independently alkyl, cycloalkyl, or aryl; or each R5 and R6, together with the nitrogen atom to which they are attached, independently form an unsubstituted heterocyclic alkyl or unsubstituted heterocyclic aryl; and X is —S— or —O—; and n is 2, 3, or 4.

The invention concerns a method for the generation of a polypeptide with specific binding properties to a predetermined target molecule which are not naturally inherent to that polypeptide. At the same time an optimization of the binding specifity and a process of production are described. The invention further concerns a method for the identification and modification of specific amino acid positions within a polypeptide scaffold.

The invention belongs to the field of genetic engineering and medicines, and particularly relates to a method for performing Hemopexin protein specific induction and maintaining selective polarization of microglial cells, and applications thereof in treatment of spinal cord injury repair. According to the main technical scheme, the method comprises the following steps: (I) transplanting microglial cells into Hemopexin-knockout mice spinal cord to hinder the microglial cells to be selectively polarized; and (II) co-incubating the Hemopexin protein and microglial cells to be capable of inducing and maintaining the selective polarization of the microglial cells. The Hemopexin-induced microglial cells show an M2 phenotype, so that the repair of the spinal cord nerve injury can be effectively promoted.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analyzed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO / 2008 / 031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.